ADAPTIVE BIOTECHNOLOGIES CORPORATION Finite-Lived Intangible Asset, Expected Amortization, Year One
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $1.70 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $1.70M 10-K · filed 2026-02-26 |
| 2024-12-31 | $1.70M 10-K · filed 2025-03-03 |
| 2023-12-31 | $1.70M 10-K · filed 2024-02-29 |
| 2022-12-31 | $1.70M 10-K · filed 2023-02-14 |
| 2022-09-30 | $1.70M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.70M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $1.70M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $1.70M 10-K · filed 2022-02-15 |
| 2021-09-30 | $1.70M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $1.70M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $1.70M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.70M 10-K · filed 2021-02-24 |
| 2020-09-30 | $1.70M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |